Anebulo Pharmaceuticals Inc.
ANEB | OTC
$1.12
+$0.25 (+28.74%)
At close: Mar 18, 2026, 3:46 PM ET
Market Data
Market Cap $35.48M
Enterprise Value N/A
Beta -0.70
Average Volume N/A
Shares Outstanding (Diluted) 41.08M
Shares Change YoY N/A
Institutional Ownership N/A
Exchange NASDAQ
ISIN N/A
Valuation
PE Ratio -5.33
Forward PE N/A
PEG Ratio -0.32
Forward PEG N/A
PS Ratio N/A
Forward PS N/A
PB Ratio 5.76
P/FCF Ratio N/A
P/Adj. FCF Ratio N/A
P/OCF Ratio N/A
EV/Sales N/A
EV/EBIT N/A
EV/EBITDA -4.40
EV/FCF N/A
Earnings Yield N/A
FCF Yield N/A
Adj. FCF Yield N/A
Financial Health
Net Cash $9.04M
Total Debt N/A
Cash & Short-Term Investments N/A
Total Assets N/A
Current Ratio 17.34
Quick Ratio N/A
Debt / Equity Ratio N/A
Debt / EBITDA N/A
Debt / FCF N/A
OCF / Debt N/A
Interest Coverage -26.70
Altman Z-Score N/A
Piotroski F-Score 1
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin N/A
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue N/A
SBC Impact (per share) -17.7%
Returns
Return on Assets -78.9%
Return on Equity -67.8%
Return on Invested Capital -89.9%
Return on Capital Employed N/A
Return on Tangible Assets N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count N/A
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $6
Price Target Upside N/A
Income Statement
Revenue $0
Gross Profit N/A
Operating Income N/A
EBITDA N/A
Net Income $-7.98M
EPS (Diluted) -$0.21
Revenue / Employee N/A
Profit / Employee N/A
Employees N/A
Add to Watchlist
Select watchlists to add or remove ANEB